<!doctype html>
<html>
<head>
<meta charset="utf-8">
<meta name="status" content="jhi-status-served" />
<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0">
<meta content="True" name="HandheldFriendly">
<title>The indication changed for fenofibrates</title>
<style type="text/css">
@media screen and (max-width:568px){
	.desktop_wrapper,.mobile_tds_disappear{	
		display:none !important;
		visibility:hidden !important;		
	}	
	.mobile_wrapper, .mobile_wrapper_85{
		width:100% !important;
		display:table !important;
		visibility:visible !important;
		overflow: visible !important;          
		max-height:none !important;
		font-size:100% !important;		
	}	
	.mobile_wrapper_85{
		width:85% !important;
	}
	.both_wrapper{
		width:100% !important;
		display:table !important;
	}
	.mobile_tds{
		width:100% !important;
		display:table !important;
	}
	.md_alert_logo,.top_image_mobile,.no_additional_cv_benefit_mobile,.chart_mobile{
		width:100% !important;
		height:auto !important;
	}
	.chart_mobile{
		width:86% !important;
	}
    .asterisk_accord_lipid_study_para_mobile,.accord_lipid_study_para_mobile{
		margin-top:8px !important;
		margin-left:23px !important;		
	}
	.accord_lipid_study_para_mobile{
		margin-left:inherit !important;		
		margin-right:40px !important;
	}
	.full_width_para,.full_width_para_bottom_blue_box_a,.full_width_para_bottom_blue_box_b,.full_width_para_bottom_blue_box_c,.full_width_para_bottom_blue_box_d,.full_width_para_bottom_blue_box_e,.full_width_para_f,.full_width_para_headlines{
		margin-left:25px !important;
		margin-right:25px !important;
	}
	.full_width_para_bottom_blue_box_a{
		font-size:27px !important;
	}
	.full_width_para_bottom_blue_box_b{
		font-size:24px !important;
	}
	.full_width_para_bottom_blue_box_c{
		font-size:19px !important;
	}
	.full_width_para_bottom_blue_box_d{
		font-size:16px !important;
	}
	.full_width_para_bottom_blue_box_e{
		font-size:14px !important;
	}
	.full_width_para_f{
		font-size:14px !important;
	}
	.full_width_para_headlines{
		font-size:22px !important;
	}
	.bullet_para{
		margin-left:25px !important;
	}
	.after_bullet_para{
		margin-right:25px !important;
	}
	.dagger_in_amarin_statement{
		margin-left:20px !important;
	}
	.bottom_three_paras_first_two{
		margin-left:50px !important;
		margin-right:50px !important;
	}
	.bottom_three_paras{
		margin-left:30px !important;
		margin-right:30px !important;
	}
	.two_cell_amarin_statement{
		margin-top:12px !important;
	}
	
} 
</style>

</head>

<body>
<table cellpadding="0" cellspacing="0" width="550" align="center" class="both_wrapper">
<tr>
<td align="left" valign="top" style="padding-bottom:20px;">
<img class="md_alert_logo" src="http://www.alertmarketingmail.com/email/JHCE/1logo/images/eMD_header_2014.gif" width="550" height="94" />
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="550" align="center" class="desktop_wrapper">
<tr>
<td align="left" valign="top" style="font-size:0px;line-height:0px;">
<img src="images/26524_desktop_slices_02.png" width="550" height="348" />
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" align="center" class="mobile_wrapper" style="display:none;visibility:hidden;overflow:hidden;max-height:0px;font-size:0px;">
<tr>
<td align="left" valign="top" class="mobile_tds">
<img src="images/26524_mobile_slices_02.png" class="top_image_mobile" />
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="550" align="center" class="desktop_wrapper">
<tr>
<td align="left" valign="top">
<p style="font-family:Arial Narrow, Arial, Helvetica, sans-serif;font-size:15px;color:#23355d;margin:5px 100px 0px 63px;"><b>ACCORD-Lipid study found no cardiovascular benefit<sup style="line-height:0;font-size:80%;">2</sup>*</b></p>
<table cellpadding="0" cellspacing="0" align="left">
<tr>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#f5da06;margin:10px 5px 0px 65px;">&bull;</p>
</td>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:14px;margin:10px 10px 0px 0px;color:#5c5b5b;">Failed to demonstrate incremental CV benefit
from adding fenofibrates to statin</p>
</td>
</tr>
</table>
</td>
<td align="left" valign="top" style="font-size:0px;line-height:0px;">
<img src="images/26524_desktop_slices_04.png" width="173" height="76" />
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="550" align="center" class="desktop_wrapper">
<tr>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#f5da06;margin:10px 5px 0px 65px;">&bull;</p>
</td>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:14px;margin:10px 100px 0px 0px;color:#5c5b5b;">Showed no CV benefit despite raising HDL-C and reducing
triglyceride (TG) levels among statin-treated patients with
well-controlled LDL-C</p>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" align="center" class="mobile_wrapper" style="display:none;visibility:hidden;overflow:hidden;max-height:0px;font-size:0px;">
<tr>
<td class="mobile_tds">
<p style="font-family:Arial Narrow, Arial, Helvetica, sans-serif;font-size:19px;color:#23355d;margin:0px 100px 0px 25px;">
<b>ACCORD-Lipid study found no cardiovascular benefit<sup style="line-height:0;font-size:80%;">2</sup>*</b>
</p>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" align="center" class="mobile_wrapper" style="display:none;visibility:hidden;overflow:hidden;max-height:0px;font-size:0px;">
<tr>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 25px;">&bull;</p>
</td>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 30px 0px 0px;color:#5c5b5b;">Failed to demonstrate incremental CV benefit
from adding fenofibrates to statin</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 25px;">&bull;</p>
</td>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 30px 0px 0px;color:#5c5b5b;">Showed no CV benefit despite raising HDL-C and reducing
triglyceride (TG) levels among statin-treated patients with
well-controlled LDL-C</p>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="550" align="center" class="both_wrapper">
<tr>
<td align="left" valign="top">
<p class="asterisk_accord_lipid_study_para_mobile" style="font-family:Arial, Helvetica, sans-serif;font-size:12px;margin:12px 0px 0px 60px;color:#5c5b5b;">*</p>
</td>
<td align="left" valign="top">
<p class="accord_lipid_study_para_mobile" style="font-family:Arial Narrow, Arial, Helvetica, sans-serif;font-size:11px;margin:12px 120px 20px 0px;color:#5c5b5b;">The ACCORD-Lipid study was not designed to test the effect of lowering
TG levels in patients with high levels after statin therapy.</p>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="550" align="center" class="desktop_wrapper">
<tr>
<td width="62" align="left" valign="top">&nbsp;
</td>
<td width="400" align="left" valign="top" style="border-top:solid 3px #e7e7e8;border-bottom:solid 3px #e7e7e8;">
<p style="font-family:Arial Narrow, Arial, Helvetica, sans-serif;font-size:20px;color:#23355d;margin:15px 0px 15px 0px;"><b>Fenofibrates may lead to lipid imbalance</b></p>
</td>
<td width="86" align="left" valign="top">&nbsp;
</td>
</tr>
</table>


















<table cellpadding="0" cellspacing="0" width="550" align="center" class="desktop_wrapper">
<tr>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:15px;color:#23355d;margin:15px 50px 0px 63px;"><b>Adverse impact of fenofibrates<br />
on LDL-C in statin-treated patients</b></p>
<table cellpadding="0" cellspacing="0" align="left">
<tr>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#f5da06;margin:10px 5px 0px 65px;">&bull;</p>
</td>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:14px;margin:10px 10px 0px 0px;color:#5c5b5b;">May blunt statinsâ€™ LDL-C-lowering effect in
patients with high TG<sup style="line-height:0;font-size:80%;">3-5</sup></p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#f5da06;margin:10px 5px 0px 65px;">&bull;</p>
</td>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:14px;margin:10px 10px 0px 0px;color:#5c5b5b;">Raises LDL-C in patients with very high TG<sup style="line-height:0;font-size:80%;">6</sup></p>
</td>
</tr>
</table>
</td>
<td align="left" valign="top" style="font-size:0px;line-height:0px;">
<p style="margin:37px 0px 20px 0px;"><img src="images/26524_desktop_slices_06.png" width="173" height="103" /></p>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" align="center" class="mobile_wrapper" style="display:none;visibility:hidden;overflow:hidden;max-height:0px;font-size:0px;">
<tr>
<td align="left" valign="top" class="mobile_tds">
<p style="margin:0px 0px 20px 0px;"><img src="images/26524_mobile_slices_04.png" class="no_additional_cv_benefit_mobile" /></p>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" class="mobile_wrapper_85" align="center" style="display:none;visibility:hidden;overflow:hidden;max-height:0px;font-size:0px;">
<tr>
<td align="left" valign="top" style="border-top:solid 4px #e7e7e8;border-bottom:solid 4px #e7e7e8;">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:20px;color:#23355d;margin:10px 0px 10px 0px;"><b>Fenofibrates may lead to lipid imbalance</b></p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p style="font-family:Arial Narrow, Arial, Helvetica, sans-serif;font-size:19px;color:#23355d;margin:20px 0px 10px 0px;"><b>Adverse impact of fenofibrates on
LDL-C in statin-treated patients</b></p>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" align="center" class="mobile_wrapper" style="display:none;visibility:hidden;overflow:hidden;max-height:0px;font-size:0px;">
<tr>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 25px;">&bull;</p>
</td>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 30px 0px 0px;color:#5c5b5b;">May blunt statinsâ€™ LDL-C-lowering effect in
patients with high TG<sup style="line-height:0;font-size:80%;">3-5</sup></p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 25px;">&bull;</p>
</td>
<td align="left" valign="top">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 30px 30px 0px;color:#5c5b5b;">Raises LDL-C in patients with very high TG<sup style="line-height:0;font-size:80%;">6</sup></p>
</td>
</tr>
</table>

<table cellpadding="0" cellspacing="0" align="center" class="mobile_wrapper" style="display:none;visibility:hidden;overflow:hidden;max-height:0px;font-size:0px;">
<tr>
<td align="left" valign="top" class="mobile_tds">
<p style="margin:0px 0px 20px 0px;"><img src="images/26524_mobile_slices_06.png" class="no_additional_cv_benefit_mobile" /></p>
</td>
</tr>
</table>
<!--<table cellpadding="0" cellspacing="0" align="center" class="mobile_wrapper" style="display:none;visibility:hidden;overflow:hidden;max-height:0px;font-size:0px;">
<tr>
<td align="left" valign="top">
<p style="margin:20px 0px 15px 0px;"><img src="images/26524_mobile_slices_06.png" width="320" height="146" /></p>
</td>
</tr>
</table>-->
<table cellpadding="0" cellspacing="0" align="center" class="mobile_wrapper" style="display:none;visibility:hidden;overflow:hidden;max-height:0px;font-size:0px;">
<tr>
<td align="left" valign="top" style="background-color:#ecf6fd;font-size:15px;">&nbsp;

</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" align="center" class="mobile_wrapper" style="display:none;visibility:hidden;overflow:hidden;max-height:0px;font-size:0px;">
<tr>
<td align="left" valign="top" style="background-color:#23355d;font-size:15px;width:95%;">
<p style="font-family:Arial, helvetica, sans-serif;font-size:18px;color:#FFFFFF;margin:15px 0px 15px 25px;">Consider VASCEPA: The only
prescription pure EPA</p>
</td>
<td align="left" valign="top" style="background-color:#ecf6fd;font-size:15px;">&nbsp;

</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" align="center" class="mobile_wrapper" style="display:none;visibility:hidden;overflow:hidden;max-height:0px;font-size:0px;">
<tr>
<td align="left" valign="top" style="background-color:#ecf6fd;font-size:18px;">
<p style="font-family:Arial, Helvetica, sans-serif;margin:15px 15px 15px 25px;color:#23355d;"><b>In patients with TG levels &ge;200 mg/dL
to &lt;500 mg/dL, prescription pure EPA
VASCEPA has been found to lower
TG and atherogenic lipids without
raising LDL-C<sup style="line-height:0;font-size:80%;">7,8</sup></b></p>
</td>
</tr>
<tr>
<td align="left" valign="top" style="font-size:25px;">&nbsp;

</td>
</tr>

<tr>
<td align="center" valign="top" style="background-color:#f5da06;">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:23px;margin:35px 20px 15px 20px;color:#23355d;"><b>The FDA reconsidered the use of fenofibrates with statins.<sup style="line-height:0;font-size:80%;">1</sup> Maybe you should too. <a href="http://www.vascepahcp.com" style="color:#23355d;text-decoration:underline;">www.vascepahcp.com</a></b></p>
<p style="margin:15px 0px 40px 0px;text-align:center;"><img src="images/26524_mobile_slices_09.png" width="118" height="81" /></p>
</td>
</tr>
</table>








<table cellpadding="0" cellspacing="0" width="550" align="center" class="desktop_wrapper">
<tr>
<td align="left" valign="top" width="40" style="font-size:17px;">&nbsp;
</td>
<td width="473" align="left" valign="top" style="background-color:#ecf6fd;font-size:17px;">&nbsp;
</td>
<td align="left" valign="top" width="35" style="background-color:#FFFFFF;font-size:17px;">&nbsp;
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="550" align="center" class="desktop_wrapper">
<tr>
<td align="left" valign="top" width="40" style="font-size:17px;">&nbsp;
</td>
<td width="414" align="left" valign="top" style="background-color:#23355d;">
<p style="font-family:Arial, helvetica, sans-serif;font-size:15px;color:#FFFFFF;margin:line-heght:35px;margin:10px 10px 10px 25px;"><b>Consider VASCEPA: The only prescription pure EPA</b></p>
</td>
<td width="59" align="left" valign="top" style="background-color:#ecf6fd;font-size:17px;color:#ecf6fd;">&nbsp;
</td>
<td width="35" align="left" valign="top" style="background-color:#FFFFFF;font-size:17px;color:#FFFFFF;">&nbsp;
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="550" align="center" class="desktop_wrapper">
<tr>
<td align="left" valign="top" width="40" style="font-size:15px;">&nbsp;
</td>
<td width="473" align="left" valign="top" style="background-color:#ecf6fd;font-size:15px;">
<p style="font-family: Arial, Helvetica, sans-serif;font-size:14px;color:#23355d;margin:20px 0px 25px 25px;">
<b>In patients with TG levels &ge;200 mg/dL to &lt;500 mg/dL, prescription
pure EPA VASCEPA has been found to lower TG and atherogenic
lipids without raising LDL-C<sup style="line-height:0;font-size:80%;">7,8</sup></b></p>


</td>
<td align="left" valign="top" width="35" style="background-color:#FFFFFF;font-size:15px;">&nbsp;
</td>
</tr>
<tr>
<td align="left" valign="top" width="40" style="font-size:15px;">&nbsp;
</td>
<td width="473" align="left" valign="top" style="background-color:#ffffff;font-size:15px;">&nbsp;

</td>
<td align="left" valign="top" width="35" style="background-color:#ffffff;font-size:15px;">&nbsp;
</td>
</tr>
<tr>
<td align="left" valign="top" width="40" style="background-color:#ffffff;font-size:15px;">&nbsp;
</td>
<td width="473" align="left" valign="top" style="background-color:#f5da06;font-size:15px;">
<p style="font-family: Arial, Helvetica, sans-serif;font-size:17px;color:#23355d;margin:30px 90px 0px 90px;text-align:center;">
<b>The FDA reconsidered the use of fenofibrates with statins.<sup style="line-height:0;font-size:80%;">1</sup> <br />Maybe you should too. <a href="http://www.vascepahcp.com" style="text-decoration:underline;color:#23355d;">www.vascepahcp.com</a></b></p>
<p style="margin:20px 0px 35px 0px;text-align:center;"><img src="images/26524_desktop_slices_09.png" width="142" height="81" /></p>
</td>
<td align="left" valign="top" width="35" style="background-color:#ffffff;font-size:15px;">&nbsp;
</td>
</tr>
</table>




<table cellpadding="0" cellspacing="0" width="550" align="center" class="both_wrapper">
<tr>
<td align="left" valign="top">
<p class="full_width_para_headlines" style="font-family:Arial, Helvetica, sans-serif;font-size:17px;color:#23355d;margin:20px 35px 0px 90px;"><b>INDICATION AND LIMITATIONS OF USE FOR VASCEPA</b></p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="full_width_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 90px;color:#5c5b5b;">VASCEPA<sup style="line-height:0;font-size:80%;">&reg;</sup> (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (&ge;500 mg/dL) hypertriglyceridemia.</p>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="550" align="center" class="both_wrapper">
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">The effect of VASCEPA on cardiovascular mortality and morbidity or on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined</p>
</td>
</tr>
</table>

<table cellpadding="0" cellspacing="0" width="550" align="center" class="both_wrapper">
<tr>
<td align="left" valign="top">
<p class="full_width_para_headlines" style="font-family:Arial, Helvetica, sans-serif;font-size:17px;color:#23355d;margin:35px 35px 0px 90px;"><b>IMPORTANT SAFETY INFORMATION FOR VASCEPA</b></p>
</td>
</tr>
</table>

<table cellpadding="0" cellspacing="0" width="550" align="center" class="both_wrapper">
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">Use with caution in patients with known hypersensitivity to fish and/or shellfish</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">The most common reported adverse reaction (incidence &gt;2% and greater than placebo) was arthralgia (2.3% VASCEPA, 1.0% placebo)</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">Patients receiving treatment with VASCEPA and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">Patients should be advised to swallow VASCEPA capsules whole; not to break open, crush, dissolve, or chew VASCEPA</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">Adverse events may be reported by calling <span style="white-space:nowrap;">1-855-VASCEPA</span> or the FDA at 1-800-FDA-1088</p>
</td>
</tr>
</table>


<table cellpadding="0" cellspacing="0" width="550" align="center" class="both_wrapper">
<tr>
<td align="left" valign="top">
<p class="full_width_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:35px 35px 0px 90px;color:#5c5b5b;">Please see full <a href="https://www.vascepahcp.com/wp-content/uploads/2015/03/vascepa-pi-ppi-clean-P00120G-1-15.pdf" style="text-decoration:underline;color:#23355d;"><b>Prescribing Information</b></a> for more information on VASCEPA.</p>
</td>
</tr>
</table>

<table cellpadding="0" cellspacing="0" width="550" align="center" class="both_wrapper">
<tr>
<td align="left" valign="top">
<p class="full_width_para" style="font-family:Arial, Helvetica, sans-serif;font-size:17px;color:#23355d;margin:25px 35px 0px 90px;"><b>IMPORTANT INFORMATION FOR HCPs ABOUT
VASCEPA AS AN ADD-ON TO STATINS IN
PATIENTS WITH HIGH (200-499 mg/dL) TG
LEVELS</b></p>
</td>
</tr>
</table>


<table cellpadding="0" cellspacing="0" width="550" align="center" class="both_wrapper">
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">Supportive but not conclusive research shows that consumption of
EPA and DHA omega-3 fatty acids may reduce the risk of coronary
heart disease. VASCEPA should not be taken in place of a healthy
diet and lifestyle or statin therapy</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">The ANCHOR trial demonstrates that VASCEPA lowers TG levels
in patients with high (&ge;200 mg/dL and &lt;500 mg/dL) TG levels not
controlled by diet and statin therapy</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">In the ANCHOR trial, VASCEPA 4 g/day significantly reduced TG,
non-HDL-C, Apo B, VLDL-C, TC, and HDL-C levels from baseline
relative to placebo in patients with high (&ge;200 mg/dL and
&lt;500 mg/dL) TG levels not controlled by diet and statin therapy</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">The reduction in TG observed with VASCEPA was not associated
with elevations in LDL-C relative to placebo</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">VASCEPA is not FDA-approved for the treatment of statin-treated
patients with mixed dyslipidemia and high (&ge;200 mg/dL and
&lt;500 mg/dL) TG levels due to current uncertainty regarding the
benefit, if any, of drug-induced changes in lipid/lipoprotein
parameters beyond statin-lowered LDL-C on cardiovascular risk
among statin-treated patients with residually high TG. No
prospective study has been conducted to test and support what,
if any, benefit exists</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">Recent cardiovascular outcomes trials (ACCORD Lipid, AIM-HIGH,
and HPS2-THRIVE), while not designed to test the effect of
lowering TG levels in patients with high TG levels after statin
therapy, each failed to demonstrate incremental cardiovascular
benefit of adding a second lipid-altering drug (fenofibrate or
formulations of niacin), despite raising HDL-C and reducing TG
levels, among statin-treated patients with well-controlled LDL-C</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">VASCEPA is not FDA-approved to reduce the risk of coronary
heart disease</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">The effect of VASCEPA on the risk of cardiovascular mortality and
morbidity has not been determined</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">A cardiovascular outcomes study of VASCEPA designed to
evaluate the efficacy of VASCEPA in reducing cardiovascular
mortality and morbidity in a high-risk patient population on statin
therapy is currently underway (REDUCE-IT)</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">VASCEPA may not be eligible for reimbursement under government
healthcare programs (such as Medicare and Medicaid) to reduce the
risk of coronary heart disease or for treatment of statin-treated
patients with mixed dyslipidemia and high (&ge;200 mg/dL and
&lt;500 mg/dL) TG levels. We encourage you to check for yourself</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 90px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 25px 0px;color:#5c5b5b;">The ANCHOR trial was sponsored by Amarin Pharma, Inc. and
its affiliates</p>
</td>
</tr>
</table>

<table cellpadding="0" cellspacing="0" width="550" align="center" class="both_wrapper">
<tr>
<td align="left" valign="top" class="mobile_tds_disappear" width="70">&nbsp;

</td>
<td align="left" valign="top" width="455" style="background-color:#ecf6fd;">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:24px;color:#23355d;margin:20px 20px 0px 20px;" class="full_width_para_bottom_blue_box_a"><b>Results from the ANCHOR
study<sup style="line-height:0;font-size:80%;">7,9</sup></b></p>
<p style="font-family:Arial, Helvetica, sans-serif;font-size:19px;color:#23355d;margin:10px 0px 0px 20px;" class="full_width_para_bottom_blue_box_b">Co-administration therapy with
statins for additional lipid
management in mixed dyslipidemia<sup style="line-height:0;font-size:80%;">&dagger;</sup></p>


<table cellpadding="0" cellspacing="0" width="455" align="center" class="both_wrapper">
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 17px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">The effects of VASCEPA as add-on therapy to treatment with
statins were evaluated in a randomized, placebo-controlled,
double-blind, parallel-group study of 453 adult patients (226
receiving VASCEPA and 227 receiving placebo) with persistent
high triglyceride levels (&ge;200 mg/dL and &lt;500 mg/dL) despite
statin therapy</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 17px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">All patients were receiving statin therapy (atorvastatin,
rosuvastatin, or simvastatin) and were treated to LDL-C goal prior
to randomization</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 17px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">Patients were randomized to either VASCEPA or placebo and
treated for 12 weeks with statin co-therapy</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 17px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">The same statin at the same dose was continued throughout
the study</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 17px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">The median baseline TG and LDL-C levels in these patients were
259 mg/dL and 83 mg/dL, respectively</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 17px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">The randomized population in this study was mostly
Caucasian (96%) and male (61%)</p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 17px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">The mean age was 61 years and the mean body mass index was
33 kg/m<sup style="line-height:0;font-size:80%;">2</sup></p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;color:#f5da06;margin:8px 5px 0px 17px;">&bull;</p>
</td>
<td align="left" valign="top">
<p class="after_bullet_para" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:8px 35px 0px 0px;color:#5c5b5b;">Seventy-three percent (73%) of patients had diabetes at baseline</p>
</td>
</tr>

</table>


</td>
<td align="left" valign="top" class="mobile_tds_disappear" width="25">&nbsp;

</td>
</tr>
</table>

<table cellpadding="0" cellspacing="0" width="550" align="center" class="both_wrapper">
<tr>
<td align="left" valign="top" class="mobile_tds_disappear" width="70">&nbsp;

</td>
<td align="right" valign="top" width="18" style="background-color:#ecf6fd;">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:11px;color:#5c5b5b;margin:30px 0px 30px 0px;" class="two_cell_amarin_statement"><sup style="line-height:0;font-size:80%;" class="dagger_in_amarin_statement">&dagger;</sup></p>
</td>
<td align="left" valign="top" width="404" style="background-color:#ecf6fd;border-bottom:solid 2px #c2def1">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:11px;color:#5c5b5b;margin:30px 0px 30px 0px;" class="two_cell_amarin_statement">Amarin may now disclose truthful, non-misleading information not included in the
VASCEPA Prescribing Information to healthcare professionals pursuant to a federal
court order issued on March 8, 2016 in <i>Amarin Pharma, Inc. et al v. United States Food
and Drug Administration et al</i>, 119 F. Supp. 3d. 196 (S.D.N.Y. 2015).</p>
</td>
<td align="right" valign="top" width="32" style="background-color:#ecf6fd;">&nbsp;

</td>
<td align="left" valign="top" class="mobile_tds_disappear" width="24">&nbsp;

</td>
</tr>
</table>

<table cellpadding="0" cellspacing="0" width="550" align="center" class="both_wrapper">
<tr>
<td align="left" valign="top" class="mobile_tds_disappear" width="70">&nbsp;

</td>
<td align="left" valign="top" width="455" style="background-color:#ecf6fd;">
<p style="font-family:Arial, Helvetica, sans-serif;font-size:15px;color:#23355d;margin:20px 20px 0px 20px;" class="full_width_para_bottom_blue_box_c"><b>Response to the addition of VASCEPA
to ongoing statin therapy in patients
with high triglyceride levels<br />
(&ge;200 mg/dL and &lt;500 mg/dL)</b></p>
<p style="font-family:Arial, Helvetica, sans-serif;font-size:14px;color:#23355d;margin:8px 20px 0px 20px;" class="full_width_para_bottom_blue_box_d">The changes in the major lipoprotein lipid
parameters for the groups receiving VASCEPA
plus statin or placebo plus statin are shown in
the table.</p>
<p class="full_width_para_bottom_blue_box_e" style="font-family:Arial, Helvetica, sans-serif;font-size:11px;margin:8px 25px 15px 20px;color:#5c5b5b;">(Data reviewed and confirmed by the FDAâ€”indication not
approved by the FDA)</p>
</td>
<td align="left" valign="top" class="mobile_tds_disappear" width="25">&nbsp;

</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="550" align="center" class="desktop_wrapper">
<tr>
<td width="69" align="left" valign="top">&nbsp;
</td>
<td width="20" align="left" valign="top" style="background-color:#ecf6fd;">&nbsp;
</td>
<td width="434" align="left" valign="top" style="font-size:0px;line-height:0px;background-color:#ecf6fd;">
<img src="images/26524_desktop_slices_13.png" width="410" height="173" />
</td>
<td width="25" align="left" valign="top">&nbsp;
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" align="center" class="mobile_wrapper" style="display:none;visibility:hidden;overflow:hidden;max-height:0px;font-size:0px;">
<tr>
<td align="center" valign="top" class="mobile_tds" style="background-color:#ecf6fd;">
<img src="images/26524_mobile_slices_13.png" class="chart_mobile" />
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="550" align="center" class="both_wrapper">
<tr>
<td align="left" valign="top" class="mobile_tds_disappear" width="70">&nbsp;

</td>
<td align="left" valign="top" width="455" style="background-color:#ecf6fd;">
<p class="full_width_para_bottom_blue_box_e" style="font-family:Arial, Helvetica, sans-serif;font-size:11px;margin:8px 25px 0px 20px;color:#5c5b5b;">% change=median percent change from baseline.</p>
<p class="full_width_para_bottom_blue_box_e" style="font-family:Arial, Helvetica, sans-serif;font-size:11px;margin:0px 25px 0px 20px;color:#5c5b5b;">
Difference=median of (VASCEPA % change-placebo % change) (Hodges-Lehmann
Estimate).</p>
<p class="full_width_para_bottom_blue_box_e" style="font-family:Arial, Helvetica, sans-serif;font-size:11px;margin:0px 25px 0px 20px;color:#5c5b5b;">
<i>P</i> values from Wilcoxon rank sum test.</p>
<p class="full_width_para_bottom_blue_box_e" style="font-family:Arial, Helvetica, sans-serif;font-size:11px;margin:8px 25px 0px 20px;color:#5c5b5b;">
VASCEPA significantly reduced TG, non-HDL-C, Apo B, VLDL-C, TC, and HDL-C
levels from baseline relative to placebo. The reduction in TG observed with VASCEPA
was not associated with elevations in LDL-C relative to placebo.</p>
<p class="full_width_para_bottom_blue_box_e" style="font-family:Arial, Helvetica, sans-serif;font-size:11px;margin:8px 25px 30px 20px;color:#5c5b5b;">
The effect of VASCEPA on cardiovascular mortality and morbidity in patients with mixed
dyslipidemia has not been determined.</p>
</td>
<td align="left" valign="top" class="mobile_tds_disappear" width="25">&nbsp;

</td>
</tr>
</table>



<table cellpadding="0" cellspacing="0" width="550" align="center" class="both_wrapper">
<tr>
<td align="left" valign="top">
<p class="full_width_para_f" style="font-family:Arial, Helvetica, sans-serif;font-size:18px;margin:10px 35px 0px 90px;color:#5c5b5b;"><b>References: 1.</b> Department of Health and Human Services. AbbVie
Inc., et al; Withdrawal of approval of indications related to the
coadministration with statins in applications for niacin extended-release
tablets and fenofibric acid delayed-release capsules.
<a href="https://www.federalregister.gov/documents/2016/04/18/2016-08887/
abbvie-inc-et-al-withdrawal-of-approval-of-indications-related-to-thec
oadministration-with-statins" style="text-decoration:none;color:#5c5b5b;">https://www.federalregister.gov/<br />documents/2016/04/18/2016-08887/abbvie-inc-et-al-withdrawal-of-approval-of-indications-related-to-the<br />coadministration-with-statins</a>. Published April 18, 2016. Accessed
March 22, 2017. <b>2.</b> ACCORD Study Group; Ginsberg HN, Elam MB,
Lovato LC, et al. Effects of combination lipid therapy in type 2
diabetes mellitus. <i>N Engl J Med</i>. 2010;362(17):1563â€“1574.
<b>3.</b> Davidson MH, Rosenson RS, Maki KC, et al. Effects of fenofibric
acid on carotid intima-media thickness in patients with mixed
dyslipidemia on atorvastatin therapy: randomized, placebo-controlled
study (FIRST). <i>Arterioscler Thromb Vasc Biol.</i>
2014;34(6):1298â€“1306. <b>4.</b> Ouwens MJ, Nauta J, Ansquer JC,
Driessen S. Systematic literature review and meta-analysis of dual
therapy with fenofibrate or fenofibric acid and a statin versus a double
or equivalent dose of statin monotherapy. <i>Curr Med Res Opin.</i>
2015;31(12):2273â€“2285. <b>5.</b> Ballantyne CM, Jones PH, Kelly MT, et
al. Long-term efficacy of adding fenofibric acid to moderate-dose
statin therapy in patients with persistent elevated triglycerides.
<i>Cardiovasc Drugs Ther.</i> 2011;25(1):59â€“67. <b>6.</b> Goldberg AC,
Schonfeld G, Feldman EB, et al. Fenofibrate for the treatment of type
IV and V hyperlipoproteinemias: a double-blind, placebo-controlled
multicenter US study. <i>Clin Ther.</i> 1989;11(1):69â€“83. <b>7.</b> Ballantyne CM,
Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic
acid ethyl ester (AMR101) therapy in statin-treated patients with
persistent high triglycerides (from the ANCHOR study). <i>Am J
Cardiol.</i> 2012;110(7):984â€“992. <b>8.</b> VASCEPA [package insert].
Bedminster, NJ: Amarin Pharma, Inc.; 2017. <b>9</b>. <i>Amarin Pharma, Inc.
et al v. United States Food and Drug Administration et al,</i> 119 F.
Supp. 3d. 196 (S.D.N.Y. 2015).</p>
</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" width="550" align="center" class="both_wrapper">
<tr>
<td align="center" style="font-size:30px;">
<!--<p class="bottom_three_paras_first_two" style="font-family:Arial, Helvetica, sans-serif;font-size:12px;color:#868fa1;margin:30px 12px 0px 12px;">To unsubscribe from the Amarin Pharma, Inc. program(s) in which you are currently enrolled, <a href="#" style="text-decoration:underline;color:#868fa1;"><b>click here</b></a></p>-->
<p class="bottom_three_paras_first_two" style="font-family:Arial, Helvetica, sans-serif;font-size:12px;color:#868fa1;margin:30px 35px 0px 35px;">Adverse events should be reported by calling 1-855-VASCEPA or by contacting the FDA: 1-800-FDA-1088. View the full <a href="https://www.vascepahcp.com/includes/uploads/Amarin_Privacy_Policy.pdf" style="text-decoration:underline;color:#868fa1;"><b>VASCEPA privacy policy</b></a> here.</p>
<p class="bottom_three_paras" style="font-family:Arial, Helvetica, sans-serif;font-size:12px;color:#868fa1;margin:30px 25px 0px 25px;">VASCEPA is a registered trademark of the Amarin group of companies.<br />&copy;2017 Amarin Pharma, Inc. Bedminster, NJ 07921 All rights reserved. VAS-00113 06/17</p>
<p style="margin:30px 0px 30px 0px;text-align:center;"><img src="images/26524_mobile_slices_17.png" width="229" height="49" /></p>
</td>
</tr>
</table>



</body>
</html>
